The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The two substrates of this enzyme are cyclopentanol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are cyclopentanone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is cyclopentanol:NAD+ oxidoreductase.
Some of the protesters attempted to burn down the building that housed the district committee of the PCR. The Securitate responded with tear gas and water cannons, while police beat up rioters and arrested many of them. Around 21:00 the rioters withdrew. They regrouped eventually around the Timișoara Orthodox Cathedral and started a protest march around the city, but again they were confronted by the security forces.
== Protection and management == Rhodiola rosea has not been assessed on the IUCN red list, but is listed on the CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora) Appendix II which "includes species not necessarily threatened with extinction, but in which trade must be controlled in order to avoid utilization incompatible with their survival.".
==== Systemic clinical effectiveness ==== At least seven studies have assessed transdermal progesterone. In these studies, different formulations of transdermal progesterone including creams and water-based gels (brand names Pro-Gest, Progestelle, and Pro-Femme, as well as compounded) were used, with different sample sizes (n = 6 to n = 40), at different dosages (15 to 80 mg per day), and for different durations of treatment (1.4 to 24 weeks). Venous blood progesterone levels were assessed and reported in five of the studies and in all cases were low and found not to exceed 3.5 ng/mL. It is generally accepted that progesterone levels of 5 ng/mL are necessary to inhibit mitosis and induce secretory changes in the endometrium, although some researchers have been disputed this contention. Effects on the endometrium of transdermal progesterone were assessed in three of the studies via endometrial biopsy and the results were mixed. In one study, there was no effect; in another, antiproliferative effects were observed; and in the last study, an atrophic state was observed but only in 28 of 40 (70%) of the women. Circulating progesterone levels were reported as less than 3.5 ng/mL in the first study, low and widely variable in the second study, and were not given in the third study. Moreover, the duration of the study in which no effect was observed was short at only 2 weeks, and a longer treatment period of 4 to 6 weeks is necessary to produce endometrial changes.
=== 9 May === Fourteen people were killed in RSF shelling on Abu Shouk camp. The Sudanese government ordered the shutdown of the Greater Nile Oil Pipeline carrying petroleum experts by South Sudan, citing RSF attacks.
Sources: en.wikipedia.org
=== Other treatments === Ozone therapy – There is only limited and poor-quality information available regarding the effectiveness of ozone therapy for treating foot ulcers in people with diabetes. Growth factors - There is some low-quality evidence that growth factors may increase the likelihood that diabetic foot ulcers will heal completely. Continuous diffusion of oxygen (CDO) - CDO delivers continuous oxygen to an occluded, moist wound site at much lower flow rates of 3–12 mL/h for 24 h 7 days a week for up to several weeks or months, depending on the wound status. Phototherapy - There is very weak evidence to suggest that people with foot ulcers due to diabetes may have improved healing. There is no evidence to suggest that phototherapy improves the quality of life for people with foot ulcers caused by diabetes. Sucrose-octasulfate impregnated dressing is recommended by the International Working Group on the Diabetic Foot Ulcer (IWGDF) for the treatment of non-infected, neuro-ischaemic diabetic foot ulcers that do not show an improvement with a standard of care regimen Autologous combined leucocyte, platelet and fibrin as an adjunctive treatment, in addition to best standard of care is also recommended by IWGDF However, there is only low quality evidence that such treatment is effective in treating diabetic foot ulcer. There is limited evidence that granulocyte colony-stimulating factor may not hasten the resolution of diabetic foot ulcer infection. However, it may reduce the need for surgical interventions such as amputations and hospitalizations.
== Research == From looking at the patent bank the only research that has occurred around Cetacaine has been with certain medical procedures that use Cetacaine as an anesthetic or new dispensing containers or methods. One of the only studies that are current with Cetacaine is the one that the FDA is conducting surrounding the issue of patients contracting methemoglobinemia from the use of Cetacaine. In these studies it was recorded that 319 cases were reported and out of the 319, 32 were considered life-threatening and 3 cases resulted in death.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245. PMID 23239837. Citations: 77,037. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357. PMID 30415602. Citations: 6,621. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Heart disease and stroke statistics 2005 update: a report from the American Heart Association. Circulation. 2005;111(10):e3-e244. PMID 15753209. Citations: 8,644. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747. PMID 21670242. Citations: 4,620. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. PMID 23992601. Citations: 4,366. Adams HP Jr, Del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2007;38(5):1655-1711. PMID 17515473. Citations: 4,209. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.
== S == Saltatory conduction A process in which action potentials "jump" from one node of Ranvier to the next along a myelinated axon, greatly increasing conduction speed. Schizophrenia A severe mental disorder characterized by distortions in thinking, perception, emotions, and behavior. Associated with abnormalities in dopamine signaling and cortical connectivity. Schwann cell A type of glial cell in the peripheral nervous system that forms the myelin sheath around axons, aiding in rapid signal transmission. Second messenger A molecule generated inside a cell in response to a neurotransmitter or hormone binding to a receptor. Examples include cAMP, IP₃, and Ca²⁺. Seizure A sudden, uncontrolled electrical disturbance in the brain that can cause changes in behavior, movements, or consciousness. Selective serotonin reuptake inhibitor (SSRI) A class of antidepressants that increase serotonin levels in the synaptic cleft by blocking its reabsorption into the presynaptic neuron. Semantic memory A type of long-term memory involving general world knowledge, facts, and concepts, distinct from episodic memory. Sensory neuron A neuron that responds to external stimuli such as light, touch, sound, or chemical signals and transmits sensory information to the central nervous system. Sensory cortex A region of the cerebral cortex involved in processing incoming sensory information. Includes the primary somatosensory cortex and adjacent areas.
== Early life and legal career == Kerry-Lynne Findlay was born in 1955 in Ladysmith, British Columbia, and lived in Nanaimo and Victoria; her brother Greg Findlay was a linebacker for the BC Lions Canadian Football League (CFL) team. She comes from a family with many former CFL players; Findlay's father Stephen Findlay played for the Hamilton Tigers in the 23rd Grey Cup. After graduating from Crofton House School in Vancouver, she attended the University of British Columbia, receiving a Bachelor of Arts degree in history and political science in 1975, and a law degree in 1978. She articled at Kowarsky and Company in Vancouver, then worked there as an associate for two years before briefly serving as in-house counsel for the Insurance Corporation of British Columbia. She established her own practice in 1981, then joined Connell Lightbody in 1987 before switching to Watson Goepel Maledy in 1996. During her legal career, Findlay has been active in both the national and B.C. provincial branch of the Canadian Bar Association. She held various positions in that organization including national and provincial chair of the Constitutional Law Section and member of the National Task Force on Canadian Court Reform, and she was acclaimed president of the B.C. Branch for the 1997–1998 term. Findlay was appointed Queen's Counsel in March 1999 by the Attorney General of British Columbia, and served a five-year term as a Member of the Canadian Human Rights Tribunal by appointment of the Federal Minister of Justice (2006–2011).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.